Curcumin: An orally bioavailable blocker of TNF and other pro-inflammatory biomarkers

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1672-1692

  Aggarwal, Bharat B ^a   Gupta, Subash C ^a   Sung, Bokyung ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bioavailability; chronic diseases; curcumin; inflammation; TNF; TNF blockers

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACTIVATING TRANSCRIPTION FACTOR 2; ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CURCUMIN; CYCLOSPORIN; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; LYMPHOTOXIN; MERIVA; MESALAZINE; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHENYLBUTAZONE; PHOSPHATIDYLCHOLINE; PHOSPHORYLASE KINASE; POLYPHENOL; PROSTAGLANDIN E2; PSORALEN; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE CORONARY SYNDROME; ALCOHOL INTOXICATION; ALZHEIMER DISEASE; ANKYLOSIS; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ASTHMA; ATHEROSCLEROSIS; BACTERIAL INFECTION; BETA THALASSEMIA; BILE DUCT DYSKINESIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; CROHN DISEASE; CURCUMA LONGA; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; FOOD AND DRUG ADMINISTRATION; GALLBLADDER DISEASE; GRANULOMA; HEAD AND NECK CANCER; HEALTH CARE COST; HELICOBACTER INFECTION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IN VITRO STUDY; INFLAMMATION; IRIDOCYCLITIS; IRRITABLE COLON; LIVER TOXICITY; LUNG CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; NONHUMAN; OSTEOARTHRITIS; OSTEOSARCOMA; PANCREAS CANCER; PEPTIC ULCER; PHOTOTHERAPY; PLASMA CELL GRANULOMA; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; PROCTITIS; PROSTATITIS; PROTEIN FUNCTION; PSORIASIS; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; STOMACH ULCER; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCERATIVE COLITIS; UNITED STATES; VITILIGO;

BIOAVAILABILITY; CHRONIC DISEASES; CURCUMIN; INFLAMMATION; TNF; TNF BLOCKERS;

ANIMALS; BIOLOGICAL AVAILABILITY; CURCUMIN; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881342288     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12131     Document Type: Review

References (263)

1. Abe Y, Hashimoto S, Horie T, (1999). Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res 39: 41-47.
2. Adhvaryu MR, Reddy N, Vakharia BC, (2008). Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach. World J Gastroenterol 14: 4753-4762.
3. Aggarwal BB, (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745-756.
4. Aggarwal BB, Moffat B, Harkins RN, (1984). Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 259: 686-691.
5. Aggarwal BB, Eessalu TE, Hass PE, (1985a). Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318: 665-667.
6. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, et al. (1985b). Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260: 2345-2354.
7. Aggarwal BB, Gupta SC, Kim JH, (2012). Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood 119: 651-665.
8. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, Aggarwal BB, (2006). Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69: 195-206.
9. Allam G, (2009). Immunomodulatory effects of curcumin treatment on murine schistosomiasis mansoni. Immunobiology 214: 712-727.
10. Allegri P, Mastromarino A, Neri P, (2010). Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol 4: 1201-1206.
11. Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna FD, Kresno SB, et al. (2008). The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 40: 201-210.
12. Ammar el SM, Gameil NM, Shawky NM, Nader MA, (2011). Comparative evaluation of anti-inflammatory properties of thymoquinone and curcumin using an asthmatic murine model. Int Immunopharmacol 11: 2232-2236.
13. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB, (2007). Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.
14. Appendino G, Belcaro G, Cornelli U, Luzzi R, Togni S, Dugall M, et al. (2011). Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study. Panminerva Med 53: 43-49.
15. Arafa HM, Hemeida RA, El-Bahrawy AI, Hamada FM, (2009). Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol 47: 1311-1317.
16. Ardizzone S, Bianchi Porro G, (2005). Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286.
17. Asawanonda P, Klahan SO, (2010). Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study. Photomed Laser Surg 28: 679-684.
18. Avci G, Kadioglu H, Sehirli AO, Bozkurt S, Guclu O, Arslan E, et al. (2012). Curcumin protects against ischemia/reperfusion injury in rat skeletal muscle. J Surg Res 172: e39-e46.
19. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, et al. (2004). Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279: 51163-51171.
20. Banji D, Pinnapureddy J, Banji OJ, Saidulu A, Hayath MS, (2011). Synergistic activity of curcumin with methotrexate in ameliorating Freund's Complete Adjuvant induced arthritis with reduced hepatotoxicity in experimental animals. Eur J Pharmacol 668: 293-298.
21. Bansal S, Chhibber S, (2010). Curcumin alone and in combination with augmentin protects against pulmonary inflammation and acute lung injury generated during Klebsiella pneumoniae B5055-induced lung infection in BALB/c mice. J Med Microbiol 59: 429-437.
22. Bassiouny AR, Zaky A, Kandeel KM, (2011). Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann Hepatol 10: 516-530.
23. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. (2008). Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28: 110-113.
24. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, et al. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14.
25. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. (2010a). Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev 15: 337-344.
26. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. (2010b). Product-evaluation registry of Meriva®, a curcumin- phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 52: 55-62.
27. Bereswill S, Munoz M, Fischer A, Plickert R, Haag LM, Otto B, et al. (2010). Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS ONE 5: e15099.
28. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. (1985). Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316: 552-554.
29. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, Muller M, et al. (1997). The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 77: 772-782.
30. Billerey-Larmonier C, Uno JK, Larmonier N, Midura AJ, Timmermann B, Ghishan FK, et al. (2008). Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. Inflamm Bowel Dis 14: 780-793.
31. Biswas J, Sinha D, Mukherjee S, Roy S, Siddiqi M, Roy M, (2010). Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal. Hum Exp Toxicol 29: 513-524.
32. Bosman B, (1994). Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis. Skin Pharmacol 7: 324-334.
33. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT, (1992). Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339: 89-91.
34. Brown SJ, Mayer L, (2007). The immune response in inflammatory bowel disease. Am J Gastroenterol 102: 2058-2069.
35. Buhrmann C, Mobasheri A, Busch F, Aldinger C, Stahlmann R, Montaseri A, et al. (2011). Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: role of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 286: 28556-28566.
36. Bundy R, Walker AF, Middleton RW, Booth J, (2004). Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: a pilot study. J Altern Complement Med 10: 1015-1018.
37. Burns J, Joseph PD, Rose KJ, Ryan MM, Ouvrier RA, (2009). Effect of oral curcumin on Dejerine-Sottas disease. Pediatr Neurol 41: 305-308.
38. Cai T, Mazzoli S, Bechi A, Addonisio P, Mondaini N, Pagliai RC, et al. (2009). Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study. Int J Antimicrob Agents 33: 549-553.
39. Camacho-Barquero L, Villegas I, Sanchez-Calvo JM, Talero E, Sanchez-Fidalgo S, Motilva V, et al. (2007). Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 7: 333-342.
40. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A, (1986). Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A 83: 1670-1674.
41. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. (2011). Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4: 354-364.
42. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B, (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72: 3666-3670.
43. Chainani-Wu N, Silverman S, Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, et al. (2007). A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine 14: 437-446.
44. Chan MM, (1995). Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 49: 1551-1556.
45. Chan MM, Huang HI, Fenton MR, Fong D, (1998). In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55: 1955-1962.
46. Chandran B, Goel A, (2012). A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res 26: 1719-1725.
47. Chen D, Nie M, Fan MW, Bian Z, (2008). Anti-inflammatory activity of curcumin in macrophages stimulated by lipopolysaccharides from Porphyromonas gingivalis. Pharmacology 82: 264-269.
48. Chen HW, Kuo HT, Chai CY, Ou JL, Yang RC, (2007). Pretreatment of curcumin attenuates coagulopathy and renal injury in LPS-induced endotoxemia. J Endotoxin Res 13: 15-23.
49. Chen WH, Chen Y, Cui GH, (2005). Effects of TNF-alpha and curcumin on the expression of VEGF in Raji and U937 cells and on angiogenesis in ECV304 cells. Chin Med J (Engl) 118: 2052-2057.
50. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900.
51. Cheung KL, Khor TO, Kong AN, (2009). Synergistic effect of combination of phenethyl isothiocyanate and sulforaphane or curcumin and sulforaphane in the inhibition of inflammation. Pharm Res 26: 224-231.
52. Cho JW, Lee KS, Kim CW, (2007). Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med 19: 469-474.
53. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S, (2012). Curcumin extract for prevention of type 2 diabetes. Diabetes Care 35: 2121-2127.
54. Ciftci O, Tanyildizi S, Godekmerdan A, (2010). Protective effect of curcumin on immune system and body weight gain on rats intoxicated with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Immunopharmacol Immunotoxicol 32: 99-104.
55. Cong Y, Wang L, Konrad A, Schoeb T, Elson CO, (2009). Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells. Eur J Immunol 39: 3134-3146.
56. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, Wexner SD, et al. (2006). Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4: 1035-1038.
57. Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, et al. (2011). Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol 49: 1834-1842.
58. Dayer JM, Beutler B, Cerami A, (1985). Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163-2168.
59. Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y, et al. (2007). Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig Dis Sci 52: 2993-2998.
60. Deodhar SD, Sethi R, Srimal RC, (1980). Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71: 632-634.
61. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14: 4491-4499.
62. Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, et al. (2007). A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter 12: 238-243.
63. Durgaprasad S, Pai CG, Vasanthkumar AJF, Namitha S, (2005). A pilot study of the antioxidant effect of curcumin in tropical pancreatitis. Indian J Med Res 122: 315-318.
64. El-Azab MF, Attia FM, El-Mowafy AM, (2011). Novel role of curcumin combined with bone marrow transplantation in reversing experimental diabetes: effects on pancreatic islet regeneration, oxidative stress, and inflammatory cytokines. Eur J Pharmacol 658: 41-48.
65. El-Moselhy MA, Taye A, Sharkawi SS, El-Sisi SF, Ahmed AF, (2011). The antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-alpha and free fatty acids. Food Chem Toxicol 49: 1129-1140.
66. Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G, (2010). Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 62: 1137-1141.
67. Epstein J, Docena G, MacDonald TT, Sanderson IR, (2010). Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 103: 824-832.
68. Farombi EO, Ekor M, (2006). Curcumin attenuates gentamicin-induced renal oxidative damage in rats. Food Chem Toxicol 44: 1443-1448.
69. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg SP, Nast CC, Cominelli F, (1994). Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 94: 449-453.
70. Fiers W, Brouckaert P, Devos R, Fransen L, Leroux-Roels G, Remaut E, et al. (1986). Lymphokines and monokines in anti-cancer therapy. Cold Spring Harb Symp Quant Biol 51 (Pt 1): 587-595.
71. Fleischer AB, Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, (1996). Alternative therapies commonly used within a population of patients with psoriasis. Cutis 58: 216-220.
72. Funk JL, Oyarzo JN, Frye JB, Chen G, Lantz RC, Jolad SD, et al. (2006). Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 69: 351-355.
73. Gao X, Kuo J, Jiang H, Deeb D, Liu Y, Divine G, et al. (2004). Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem Pharmacol 68: 51-61.
74. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, et al. (2005). Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120-125.
75. Geist LJ, Hopkins HA, Dai LY, He B, Monick MM, Hunninghake GW, (1997). Cytomegalovirus modulates transcription factors necessary for the activation of the tumor necrosis factor-alpha promoter. Am J Respir Cell Mol Biol 16: 31-37.
76. Golombick T, Diamond TH, Badmaev V, Manoharan A, Ramakrishna R, (2009). The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 15: 5917-5922.
77. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG, (2010). Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58: 2095-2099.
78. Gradisar H, Keber MM, Pristovsek P, Jerala R, (2007). MD-2 as the target of curcumin in the inhibition of response to LPS. J Leukoc Biol 82: 968-974.
79. Greaves MW, Weinstein GD, (1995). Treatment of psoriasis. N Engl J Med 332: 581-588.
80. Gulcubuk A, Altunatmaz K, Sonmez K, Haktanir-Yatkin D, Uzun H, Gurel A, et al. (2006). Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med A Physiol Pathol Clin Med 53: 49-54.
81. Gupta A, Vij G, Sharma S, Tirkey N, Rishi P, Chopra K, (2009). Curcumin, a polyphenolic antioxidant, attenuates chronic fatigue syndrome in murine water immersion stress model. Immunobiology 214: 33-39.
82. Gupta B, Ghosh B, (1999). Curcuma longa inhibits TNF-alpha induced expression of adhesion molecules on human umbilical vein endothelial cells. Int J Immunopharmacol 21: 745-757.
83. Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, et al. (2011). Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28: 1937-1955.
84. Gupta SC, Patchva S, Aggarwal BB, (2013). Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15: 195-218.
85. Gutierres VO, Pinheiro CM, Assis RP, Vendramini RC, Pepato MT, Brunetti IL, (2012). Curcumin-supplemented yoghurt improves physiological and biochemical markers of experimental diabetes. Br J Nutr 108: 440-448.
86. Hai L, Kawarabayashi Y, Imai Y, Honda A, Inoue R, (2011). Counteracting effect of TRPC1-associated Ca2+ influx on TNF-alpha-induced COX-2-dependent prostaglandin E2 production in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 301: G356-G367.
87. Hanai H, Sugimoto K, (2009). Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des 15: 2087-2094.
88. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. (2006). Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4: 1502-1506.
89. Hanauer SB, (1996). Inflammatory bowel disease. N Engl J Med 334: 841-848.
90. Haranaka K, Satomi N, Sakurai A, (1984). Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34: 263-267.
91. Hashem RM, Soliman HM, Shaapan SF, (2008). Turmeric-based diet can delay apoptosis without modulating NF-kappaB in unilateral ureteral obstruction in rats. J Pharm Pharmacol 60: 83-89.
92. Hastak K, Lubri N, Jakhi SD, More C, John A, Ghaisas SD, et al. (1997). Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. Cancer Lett 116: 265-269.
93. He ZY, Shi CB, Wen H, Li FL, Wang BL, Wang J, (2011). Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 29: 208-213.
94. Heidland A, Klassen A, Rutkowski P, Bahner U, (2006). The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance? J Nephrol 19 (Suppl. 10): S102-S109.
95. Heng MC, Song MK, Harker J, Heng MK, (2000). Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143: 937-949.
96. Holt PR, Katz S, Kirshoff R, (2005). Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50: 2191-2193.
97. Huang WT, Niu KC, Chang CK, Lin MT, Chang CP, (2008). Curcumin inhibits the increase of glutamate, hydroxyl radicals and PGE2 in the hypothalamus and reduces fever during LPS-induced systemic inflammation in rabbits. Eur J Pharmacol 593: 105-111.
98. Ide H, Tokiwa S, Sakamaki K, Nishio K, Isotani S, Muto S, et al. (2010). Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70: 1127-1133.
99. Jackson JK, Higo T, Hunter WL, Burt HM, (2006). The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 55: 168-175.
100. Jain SK, Rains J, Croad J, Larson B, Jones K, (2009). Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 11: 241-249.
101. James JS, (1996). Curcumin: clinical trial finds no antiviral effect. AIDS Treat News: 1-2.
102. Jang MK, Sohn DH, Ryu JH, (2001). A curcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria. Planta Med 67: 550-552.
103. Jarnerot G, (1989). Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease. Drugs 37: 73-86.
104. Jia SH, Wei H, Yu JL, Wei XD, Zhang XP, Li JC, (2010). [Protective effects of curcumin on neonatal rats with necrotizing enterocolitis]. Zhongguo Dang Dai Er Ke Za Zhi 12: 132-136.
105. Jian YT, Wang JD, Mai GF, Zhang YL, Lai ZS, (2004). [Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis]. Di Yi Jun Yi Da Xue Xue Bao 24: 1353-1358.
106. Jiang H, Deng CS, Zhang M, Xia J, (2006). Curcumin-attenuated trinitrobenzene sulphonic acid induces chronic colitis by inhibiting expression of cyclooxygenase-2. World J Gastroenterol 12: 3848-3853.
107. 2-induced fibrosis in mice]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 25: 399-401.
108. Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, Parsons HG, et al. (2000). Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 279: G641-G651.
109. Jin CY, Lee JD, Park C, Choi YH, Kim GY, (2007). Curcumin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-stimulated BV2 microglia. Acta Pharmacol Sin 28: 1645-1651.
110. Jobin C, (2008). Nf-kappa B signaling cascade and IBD: turn it down? Inflamm Bowel Dis 14 (Suppl. 2): S108-S109.
111. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, et al. (1999). Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483.
112. Joe B, Rao UJ, Lokesh BR, (1997). Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 169: 125-134.
113. Kalpravidh RW, Siritanaratkul N, Insain P, Charoensakdi R, Panichkul N, Hatairaktham S, et al. (2010). Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. Clin Biochem 43: 424-429.
114. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, et al. (2011). A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157-164.
115. Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, et al. (2011). Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 45: 365-370.
116. Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, et al. (2012). Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr 22: 50-57.
117. Kim HG, Lee JH, Lee SJ, Oh JH, Shin E, Jang YP, et al. (2012). The increased cellular uptake and biliary excretion of curcumin by quercetin: a possible role of albumin binding interaction. Drug Metab Dispos 40: 1452-1455.
118. Kim SG, Veena MS, Basak SK, Han E, Tajima T, Gjertson DW, et al. (2011). Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin Cancer Res 17: 5953-5961.
119. Kim YS, Ahn Y, Hong MH, Joo SY, Kim KH, Sohn IS, et al. (2007). Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol 50: 41-49.
120. Kochanek S, Toth M, Dehmel A, Renz D, Doerfler W, (1990). Interindividual concordance of methylation profiles in human genes for tumor necrosis factors alpha and beta. Proc Natl Acad Sci U S A 87: 8830-8834.
121. Kochanek S, Radbruch A, Tesch H, Renz D, Doerfler W, (1991). DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias. Proc Natl Acad Sci U S A 88: 5759-5763.
122. Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J, (2010). Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients. Int Immunopharmacol 10: 815-818.
123. Kositchaiwat C, Kositchaiwat S, Havanondha J, (1993). Curcuma longa Linn. in the treatment of gastric ulcer comparison to liquid antacid: a controlled clinical trial. J Med Assoc Thai 76: 601-605.
124. Kozuch PL, Hanauer SB, (2008). Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 14: 354-377.
125. Kramer B, Meichle A, Hensel G, Charnay P, Kronke M, (1994). Characterization of an Krox-24/Egr-1-responsive element in the human tumor necrosis factor promoter. Biochim Biophys Acta 1219: 413-421.
126. Kramer B, Wiegmann K, Kronke M, (1995). Regulation of the human TNF promoter by the transcription factor Ets. J Biol Chem 270: 6577-6583.
127. Kumar A, Dhawan S, Hardegen NJ, Aggarwal BB, (1998). Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55: 775-783.
128. Kuprash DV, Udalova IA, Turetskaya RL, Kwiatkowski D, Rice NR, Nedospasov SA, (1999). Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide. J Immunol 162: 4045-4052.
129. Kuprash DV, Alimzhanov MB, Tumanov AV, Grivennikov SI, Shakhov AN, Drutskaya LN, et al. (2002). Redundancy in tumor necrosis factor (TNF) and lymphotoxin (LT) signaling in vivo: mice with inactivation of the entire TNF/LT locus versus single-knockout mice. Mol Cell Biol 22: 8626-8634.
130. Kurd SK, Richardson SK, Gelfand JM, (2007). Update on the epidemiology and systemic treatment of psoriasis. Expert Rev Clin Immunol 3: 171-185.
131. Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. (2008). Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad Dermatol 58: 625-631.
132. Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN, (2007). Immune response modulation by curcumin in a latex allergy model. Clin Mol Allergy 5: 1.
133. Kuttan R, Sudheeran PC, Josph CD, (1987). Turmeric and curcumin as topical agents in cancer therapy. Tumori 73: 29-31.
134. Lahiff C, Moss AC, (2011). Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis 17: E66.
135. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, et al. (1999). Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 13: 318-322.
136. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC, (2000). Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 14: 443-447.
137. Larmonier CB, Uno JK, Lee KM, Karrasch T, Laubitz D, Thurston R, et al. (2008). Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am J Physiol Gastrointest Liver Physiol 295: G1079-G1091.
138. Lee HS, Jung KK, Cho JY, Rhee MH, Hong S, Kwon M, et al. (2007). Neuroprotective effect of curcumin is mainly mediated by blockade of microglial cell activation. Pharmazie 62: 937-942.
139. Lee JC, Kinniry PA, Arguiri E, Serota M, Kanterakis S, Chatterjee S, et al. (2010). Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat Res 173: 590-601.
140. Leitman DC, Ribeiro RC, Mackow ER, Baxter JD, West BL, (1991). Identification of a tumor necrosis factor-responsive element in the tumor necrosis factor alpha gene. J Biol Chem 266: 9343-9346.
141. Leyon PV, Kuttan G, (2003). Studies on the role of some synthetic curcuminoid derivatives in the inhibition of tumour specific angiogenesis. J Exp Clin Cancer Res 22: 77-83.
142. Liang G, Li X, Chen L, Yang S, Wu X, Studer E, et al. (2008). Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg Med Chem Lett 18: 1525-1529.
143. Liang G, Zhou H, Wang Y, Gurley EC, Feng B, Chen L, et al. (2009). Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin. J Cell Mol Med 13: 3370-3379.
144. Liepinsh DJ, Grivennikov SI, Klarmann KD, Lagarkova MA, Drutskaya MS, Lockett SJ, et al. (2006). Novel lymphotoxin alpha (LTalpha) knockout mice with unperturbed tumor necrosis factor expression: reassessing LTalpha biological functions. Mol Cell Biol 26: 4214-4225.
145. Louis E, (2001). The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha. Acta Gastroenterol Belg 64: 1-5.
146. Lubbad A, Oriowo MA, Khan I, (2009a). Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 322: 127-135.
147. Lubbad AS, Oriowo MA, Khan I, (2009b). Curcumin reverses attenuated carbachol-induced contraction of the colon in a rat model of colitis. Scand J Gastroenterol 44: 187-194.
148. McCaffrey PG, Goldfeld AE, Rao A, (1994). The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-alpha gene transcription. J Biol Chem 269: 30445-30450.
149. Martelli L, Ragazzi E, di Mario F, Martelli M, Castagliuolo I, Dal Maschio M, et al. (2007). A potential role for the vanilloid receptor TRPV1 in the therapeutic effect of curcumin in dinitrobenzene sulphonic acid-induced colitis in mice. Neurogastroenterol Motil 19: 668-674.
150. Masubuchi Y, Enoki K, Horie T, (2008). Down-regulation of hepatic cytochrome P450 enzymes in rats with trinitrobenzene sulfonic acid-induced colitis. Drug Metab Dispos 36: 597-603.
151. Matera MG, Calzetta L, Cazzola M, (2010). TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 23: 121-128.
152. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y, (2009). Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res 58: 899-908.
153. Matsuguchi T, Musikacharoen T, Ogawa T, Yoshikai Y, (2000). Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 165: 5767-5772.
154. Meja KK, Rajendrasozhan S, Adenuga D, Biswas SK, Sundar IK, Spooner G, et al. (2008). Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol 39: 312-323.
155. Mito S, Watanabe K, Harima M, Thandavarayan RA, Veeraveedu PT, Sukumaran V, et al. (2011). Curcumin ameliorates cardiac inflammation in rats with autoimmune myocarditis. Biol Pharm Bull 34: 974-979.
156. Mohandas KM, Desai DC, (1999). Epidemiology of digestive tract cancers in India. V. Large and small bowel. Indian J Gastroenterol 18: 118-121.
157. Moon DO, Jin CY, Lee JD, Choi YH, Ahn SC, Lee CM, et al. (2006). Curcumin decreases binding of Shiga-like toxin-1B on human intestinal epithelial cell line HT29 stimulated with TNF-alpha and IL-1beta: suppression of p38, JNK and NF-kappaB p65 as potential targets. Biol Pharm Bull 29: 1470-1475.
158. Moon DO, Kim MO, Lee HJ, Choi YH, Park YM, Heo MS, et al. (2008). Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide. Biochem Biophys Res Commun 375: 275-279.
159. Moon DO, Kim MO, Choi YH, Park YM, Kim GY, (2010). Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int Immunopharmacol 10: 605-610.
160. Mouzaoui S, Rahim I, Djerdjouri B, (2012). Aminoguanidine and curcumin attenuated tumor necrosis factor (TNF)-alpha-induced oxidative stress, colitis and hepatotoxicity in mice. Int Immunopharmacol 12: 302-311.
161. Muiznieks I, Doerfler W, (1994). The impact of 5′-CG-3′ methylation on the activity of different eukaryotic promoters: a comparative study. FEBS Lett 344: 251-254.
162. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT, (1991). Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32: 913-917.
163. Myokai F, Takashiba S, Lebo R, Amar S, (1999). A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci U S A 96: 4518-4523.
164. Nan B, Lin P, Lumsden AB, Yao Q, Chen C, (2005). Effects of TNF-alpha and curcumin on the expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Thromb Res 115: 417-426.
165. Nandal S, Dhir A, Kuhad A, Sharma S, Chopra K, (2009). Curcumin potentiates the anti-inflammatory activity of cyclooxygenase inhibitors in the cotton pellet granuloma pouch model. Methods Find Exp Clin Pharmacol 31: 89-93.
166. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ, (2003). Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. Am J Physiol Gastrointest Liver Physiol 284: G321-G327.
167. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W, (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998-1004.
168. Newell CL, Deisseroth AB, Lopez-Berestein G, (1994). Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol 56: 27-35.
169. Ng SC, Kamm MA, (2009). Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 15: 935-950.
170. Niederau C, Gopfert E, (1999). [The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study]. Med Klin (Munich) 94: 425-430.
171. Nishida M, Nishiumi S, Mizushina Y, Fujishima Y, Yamamoto K, Masuda A, et al. (2010). Monoacetylcurcumin strongly regulates inflammatory responses through inhibition of NF-kappaB activation. Int J Mol Med 25: 761-767.
172. Nones K, Dommels YE, Martell S, Butts C, McNabb WC, Park ZA, et al. (2009). The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr 101: 169-181.
173. Novotny V, Prieschl EE, Csonga R, Fabjani G, Baumruker T, (1998). Nrf1 in a complex with fosB, c-jun, junD and ATF2 forms the AP1 component at the TNF alpha promoter in stimulated mast cells. Nucleic Acids Res 26: 5480-5485.
174. O'Malley WE, Achinstein B, Shear MJ, (1962). Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst 29: 1169-1175.
175. Oh SW, Cha JY, Jung JE, Chang BC, Kwon HJ, Lee BR, et al. (2011). Curcumin attenuates allergic airway inflammation and hyper-responsiveness in mice through NF-kappaB inhibition. J Ethnopharmacol 136: 414-421.
176. Old LJ, (1985). Tumor necrosis factor (TNF). Science 230: 630-632.
177. Oppenheimer A, (1937). Turmeric (curcumin) in biliary diseases. Lancet 229: 619-621.
178. Pan Y, Wang Y, Cai L, Cai Y, Hu J, Yu C, et al. (2012). Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br J Pharmacol 166: 1169-1182.
179. Papadakis KA, Targan SR, (2000). Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289-298.
180. Pari L, Amali DR, (2005). Protective role of tetrahydrocurcumin (THC) an active principle of turmeric on chloroquine induced hepatotoxicity in rats. J Pharm Pharm Sci 8: 115-123.
181. Pol A, Bergers M, Schalkwijk J, (2003). Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay. In Vitro Cell Dev Biol Anim 39: 36-42.
182. Polasa K, Raghuram TC, Krishna TP, Krishnaswamy K, (1992). Effect of turmeric on urinary mutagens in smokers. Mutagenesis 7: 107-109.
183. Pope RM, Leutz A, Ness SA, (1994). C/EBP beta regulation of the tumor necrosis factor alpha gene. J Clin Invest 94: 1449-1455.
184. Prieschl EE, Novotny V, Csonga R, Jaksche D, Elbe-Burger A, Thumb W, et al. (1998). A novel splice variant of the transcription factor Nrf1 interacts with the TNFalpha promoter and stimulates transcription. Nucleic Acids Res 26: 2291-2297.
185. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K, (2001). Phase II clinical trial on effect of the long turmeric (Curcuma longa Linn) on healing of peptic ulcer. Southeast Asian J Trop Med Public Health 32: 208-215.
186. Rai B, Kaur J, Jacobs R, Singh J, (2010). Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary markers of oxidative stress. J Oral Sci 52: 251-256.
187. Ram A, Das M, Ghosh B, (2003). Curcumin attenuates allergen-induced airway hyperresponsiveness in sensitized guinea pigs. Biol Pharm Bull 26: 1021-1024.
188. Ramirez-Tortosa MC, Ramirez-Tortosa CL, Mesa MD, Granados S, Gil A, Quiles JL, (2009). Curcumin ameliorates rabbits's steatohepatitis via respiratory chain, oxidative stress, and TNF-alpha. Free Radic Biol Med 47: 924-931.
189. Rasyid A, Lelo A, (1999). The effect of curcumin and placebo on human gall-bladder function: an ultrasound study. Aliment Pharmacol Ther 13: 245-249.
190. Reddy AC, Lokesh BR, (1996). Effect of curcumin and eugenol on iron-induced hepatic toxicity in rats. Toxicology 107: 39-45.
191. Reuter S, Charlet J, Juncker T, Teiten MH, Dicato M, Diederich M, (2009). Effect of curcumin on nuclear factor kappaB signaling pathways in human chronic myelogenous K562 leukemia cells. Ann N Y Acad Sci 1171: 436-447.
192. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB, (2011). Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr 6: 93-108.
193. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL, (2005). A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2: 131-136.
194. Salh B, Assi K, Templeman V, Parhar K, Owen D, Gomez-Munoz A, et al. (2003). Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285: G235-G243.
195. Sandur SK, Ichikawa H, Pandey MK, Kunnumakkara AB, Sung B, Sethi G, et al. (2007). Role of pro-oxidants and antioxidants in the anti-inflammatory and apoptotic effects of curcumin (diferuloylmethane). Free Radic Biol Med 43: 568-580.
196. Sasaki H, Sunagawa Y, Takahashi K, Imaizumi A, Fukuda H, Hashimoto T, et al. (2011). Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34: 660-665.
197. Satoskar RR, Shah SJ, Shenoy SG, (1986). Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24: 651-654.
198. Scheinfeld N, (2004). Adalimumab (Humira): a brief review for dermatologists. J Dermatolog Treat 15: 348-352.
199. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A, (2007). Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol 73: 1434-1445.
200. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, et al. (2001). Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7: 1894-1900.
201. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. (2004). Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854.
202. Sharma RA, Steward WP, Gescher AJ, (2007a). Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol 595: 453-470.
203. Sharma S, Chopra K, Kulkarni SK, (2007b). Effect of insulin and its combination with resveratrol or curcumin in attenuation of diabetic neuropathic pain: participation of nitric oxide and TNF-alpha. Phytother Res 21: 278-283.
204. Shear MJ, Perrault A, (1944). Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Natl Cancer Inst 4: 461-476.
205. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T, (2009). Effect of dietary turmeric on breath hydrogen. Dig Dis Sci 54: 1725-1729.
206. Shishodia S, Amin HM, Lai R, Aggarwal BB, (2005). Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70: 700-713.
207. Shoskes D, Lapierre C, Cruz-Correa M, Muruve N, Rosario R, Fromkin B, et al. (2005). Beneficial effects of the bioflavonoids curcumin and quercetin on early function in cadaveric renal transplantation: a randomized placebo controlled trial. Transplantation 80: 1556-1559.
208. Shu JC, Wang HL, Ye GR, He YJ, Lu X, Fang L, (2007). [The study of therapeutic effects of curcumin on hepatic fibrosis and variation of correlated cytokine]. Zhong Yao Cai 30: 1421-1425.
209. Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, et al. (2006). The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma. Crit Care Med 34: 1874-1882.
210. Singh S, Aggarwal BB, (1995). Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270: 24995-25000.
211. Sinha R, Anderson DE, McDonald SS, Greenwald P, (2003). Cancer risk and diet in India. J Postgrad Med 49: 222-228.
212. Song WB, Wang YY, Meng FS, Zhang QH, Zeng JY, Xiao LP, et al. (2010). Curcumin protects intestinal mucosal barrier function of rat enteritis via activation of MKP-1 and attenuation of p38 and NF-kappaB activation. PLoS ONE 5: e12969.
213. Soni KB, Kuttan R, (1992). Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol 36: 273-275.
214. Sood PK, Nahar U, Nehru B, (2011). Curcumin attenuates aluminum-induced oxidative stress and mitochondrial dysfunction in rat brain. Neurotox Res 20: 351-361.
215. Srimal RC, Dhawan BN, (1973). Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol 25: 447-452.
216. Srinivasan M, (1972). Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26: 269-270.
217. Stone-Wolff DS, Yip YK, Kelker HC, Le J, Henriksen-Destefano D, Rubin BY, et al. (1984). Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med 159: 828-843.
218. Strasser EM, Wessner B, Manhart N, Roth E, (2005). The relationship between the anti-inflammatory effects of curcumin and cellular glutathione content in myelomonocytic cells. Biochem Pharmacol 70: 552-559.
219. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, et al. (2002). Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123: 1912-1922.
220. Sun J, Han J, Zhao Y, Zhu Q, Hu J, (2012). Curcumin induces apoptosis in tumor necrosis factor-alpha-treated HaCaT cells. Int Immunopharmacol 13: 170-174.
221. Takashiba S, Van Dyke TE, Shapira L, Amar S, (1995). Lipopolysaccharide- inducible and salicylate-sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect Immun 63: 1529-1534.
222. Takei S, Fernandez D, Redford A, Toyoda H, (1996). Methylation status of 5′-regulatory region of tumor necrosis factor alpha gene correlates with differentiation stages of monocytes. Biochem Biophys Res Commun 220: 606-612.
223. Tham CL, Liew CY, Lam KW, Mohamad AS, Kim MK, Cheah YK, et al. (2010). A synthetic curcuminoid derivative inhibits nitric oxide and proinflammatory cytokine synthesis. Eur J Pharmacol 628: 247-254.
224. Tong KM, Shieh DC, Chen CP, Tzeng CY, Wang SP, Huang KC, et al. (2008). Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K, Akt cascade and promotion of NF-kappaB/p300 binding in human synovial fibroblasts. Cell Signal 20: 1478-1488.
225. Tonnesen HH, de Vries H, Karlsen J, Beijersbergen van Henegouwen G, (1987). Studies on curcumin and curcuminoids. IX: investigation of the photobiological activity of curcumin using bacterial indicator systems. J Pharm Sci 76: 371-373.
226. Tsai EY, Jain J, Pesavento PA, Rao A, Goldfeld AE, (1996a). Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 16: 459-467.
227. Tsai EY, Yie J, Thanos D, Goldfeld AE, (1996b). Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. Mol Cell Biol 16: 5232-5244.
228. Tu CT, Han B, Yao QY, Zhang YA, Liu HC, Zhang SC, (2012). Curcumin attenuates Concanavalin A-induced liver injury in mice by inhibition of Toll-like receptor (TLR) 2, TLR4 and TLR9 expression. Int Immunopharmacol 12: 151-157.
229. Udalova IA, Knight JC, Vidal V, Nedospasov SA, Kwiatkowski D, (1998). Complex NF-kappaB interactions at the distal tumor necrosis factor promoter region in human monocytes. J Biol Chem 273: 21178-21186.
230. Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni JR, Das PK, (2003). Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139: 209-218.
231. Ung VY, Foshaug RR, MacFarlane SM, Churchill TA, Doyle JS, Sydora BC, et al. (2010). Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci 55: 1272-1277.
232. Uno JK, Kolek OI, Hines ER, Xu H, Timmermann BN, Kiela PR, et al. (2006). The role of tumor necrosis factor alpha in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology 131: 497-509.
233. Usharani P, Mateen AA, Naidu MU, Raju YS, Chandra N, (2008). Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D 9: 243-250.
234. Vadhan-Raj S, Weber D, Wang M, Giralt S, Alexanian R, Thomas S, et al. (2007). Curcumin downregulates NF-κB and related genes in patients with multiple myeloma: results of a phase 1/2 study. Blood 110: 357a (Abstract 1177).
235. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, et al. (2008). Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17: 1411-1417.
236. Venkataranganna MV, Rafiq M, Gopumadhavan S, Peer G, Babu UV, Mitra SK, (2007). NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol 13: 1103-1107.
237. Villegas I, Sanchez-Fidalgo S, de la, Lastra CA, (2011). Chemopreventive effect of dietary curcumin on inflammation-induced colorectal carcinogenesis in mice. Mol Nutr Food Res 55: 259-267.
238. Wallach D, (1986). Cytotoxins (tumour necrosis factor, lymphotoxin and others): molecular and functional characteristics and interactions with interferons. Interferon 7: 89-124.
239. Wan XH, Li YW, Luo XP, (2007). [Curcumin attenuated the lipid peroxidation and apoptotic liver injury in copper-overloaded rats]. Zhonghua Er Ke Za Zhi 45: 604-608.
240. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, et al. (1985). Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228: 149-154.
241. Wang SL, Li Y, Wen Y, Chen YF, Na LX, Li ST, et al. (2009). Curcumin, a potential inhibitor of up-regulation of TNF-alpha and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-kappaB and JNK pathway. Biomed Environ Sci 22: 32-39.
242. Wedel A, Sulski G, Ziegler-Heitbrock HW, (1996). CCAAT/enhancer binding protein is involved in the expression of the tumour necrosis factor gene in human monocytes. Cytokine 8: 335-341.
243. Wickenberg J, Ingemansson SL, Hlebowicz J, (2010). Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects. Nutr J 9: 43.
244. Woo HM, Kang JH, Kawada T, Yoo H, Sung MK, Yu R, (2007). Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 80: 926-931.
245. Wua ST, Sun J, Lee K, Sun Y, (2010). Docking prediction for tumor necrosis factor-α and five herbal inhibitors. Int J Eng Sci Technol 2: 4263-4277.
246. Xu YX, Pindolia KR, Janakiraman N, Chapman RA, Gautam SC, (1997). Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kB DNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 11: 49-62.
247. Yadav VR, Prasad S, Kannappan R, Ravindran J, Chaturvedi MM, Vaahtera L, et al. (2010). Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 80: 1021-1032.
248. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H, (2000). IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164: 4878-4882.
249. Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, et al. (2011). Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine 18: 205-213.
250. Yao QH, Wang DQ, Cui CC, Yuan ZY, Chen SB, Yao XW, et al. (2004). Curcumin ameliorates left ventricular function in rabbits with pressure overload: inhibition of the remodeling of the left ventricular collagen network associated with suppression of myocardial tumor necrosis factor-alpha and matrix metalloproteinase-2 expression. Biol Pharm Bull 27: 198-202.
251. Yeh CH, Chen TP, Wu YC, Lin YM, Jing Lin P, (2005). Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 125: 109-116.
252. Yoon H, Liu RH, (2007). Effect of selected phytochemicals and apple extracts on NF-kappaB activation in human breast cancer MCF-7 cells. J Agric Food Chem 55: 3167-3173.
253. Youn HS, Saitoh SI, Miyake K, Hwang DH, (2006). Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 72: 62-69.
254. Yu YM, Lin HC, (2010). Curcumin prevents human aortic smooth muscle cells migration by inhibiting of MMP-9 expression. Nutr Metab Cardiovasc Dis 20: 125-132.
255. Yun SS, Kim SP, Kang MY, Nam SH, (2010). Inhibitory effect of curcumin on liver injury in a murine model of endotoxemic shock. Biotechnol Lett 32: 209-214.
256. Zagariya A, Mungre S, Lovis R, Birrer M, Ness S, Thimmapaya B, et al. (1998). Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol 18: 2815-2824.
257. Zeng CH, Zeng P, Deng YH, Shen N, Peng ML, Liu Q, et al. (2011). [The effects of curcumin derivative on experimental steatohepatitis]. Zhonghua Gan Zang Bing Za Zhi 19: 454-459.
258. Zhang L, Wu C, Zhao S, Yuan D, Lian G, Wang X, et al. (2010a). Demethoxycurcumin, a natural derivative of curcumin attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-kappaB signaling pathways in N9 microglia induced by lipopolysaccharide. Int Immunopharmacol 10: 331-338.
259. Zhang LJ, Wu CF, Meng XL, Yuan D, Cai XD, Wang QL, et al. (2008). Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett 447: 48-53.
260. Zhang M, Deng CS, Zheng JJ, Xia J, (2006). Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 27: 1071-1077.
261. Zhang QY, Mo ZN, Liu XD, (2010b). [Reducing effect of curcumin on expressions of TNF-alpha, IL-6 and IL-8 in rats with chronic nonbacterial prostatitis]. Zhonghua Nan Ke Xue 16: 84-88.
262. Zhao C, Yang J, Wang Y, Liang D, Yang X, Li X, et al. (2010). Synthesis of mono-carbonyl analogues of curcumin and their effects on inhibition of cytokine release in LPS-stimulated RAW 264.7 macrophages. Bioorg Med Chem 18: 2388-2393.
263. Zuccotti GV, Trabattoni D, Morelli M, Borgonovo S, Schneider L, Clerici M, (2009). Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. J Biol Regul Homeost Agents 23: 119-123.